Tirzepatide vs CagriSema: Next-Generation Weight Loss Peptide Comparison | Peptpedia

Tirzepatide (SURMOUNT-1 trial, n=2,539): At 72 weeks, 5 mg achieved 15.0%, 10 mg achieved 19.5%, and 15 mg achieved 20.9% mean body weight reduction. A subsequent analysis with extended follow-up showed the 15 mg dose achieving 22.5%. This represented the highest weight loss efficacy of any approved pharmaceutical agent at the time of approval.

CagriSema (REDEFINE 1 trial, n=3,414): At 68 weeks, CagriSema 2.4/2.4 mg achieved 20.4% mean body weight reduction, with 40.4% of participants achieving >25% weight loss. This was significantly greater than the semaglutide 2.4 mg monotherapy control arm (~14.9%). The combination's unique feature is that the amylin pathway (cagrilintide) provides complementary satiety signaling to GLP-1 agonism.

Tirzepatide is a single-molecule dual GIP/GLP-1 receptor agonist built on a 39-amino-acid GIP backbone. GIP receptor activation restores GIPR sensitivity in adipose tissue, enhances adipocyte lipid handling and oxidation, and contributes to hypothalamic appetite regulation through circuits partially distinct from GLP-1 signaling. The molecule's GIP:GLP-1 potency ratio favors GIP receptor activation, meaning the GIP component is not incidental but drives a substantial portion of tirzepatide's metabolic effects beyond what GLP-1 agonism alone provides.

CagriSema co-administers two separate agents: semaglutide (a GLP-1 receptor agonist) and cagrilintide (a long-acting amylin analog). Cagrilintide targets amylin receptors (AMY1, AMY2, AMY3) and calcitonin receptors in the area postrema and hypothalamic satiety circuits. The amylin pathway addresses hedonic appetite—reward-driven eating behavior—through a mechanism distinct from GLP-1's homeostatic appetite suppression, which primarily modulates nutrient sensing and gastric emptying. Phase 2 data from cagrilintide monotherapy demonstrated dose-dependent weight loss of up to 10.8% at 26 weeks, confirming the amylin pathway contributes meaningful independent weight reduction.

Both approaches achieve multi-receptor engagement but through fundamentally different secondary pathways. Tirzepatide pairs GLP-1 with GIP (an incretin that enhances insulin sensitivity and lipid metabolism); CagriSema pairs GLP-1 with amylin (a pancreatic hormone that slows gastric emptying and suppresses glucagon). The downstream metabolic consequences of these pairings differ, and the absence of a head-to-head trial prevents direct comparison of which secondary pathway produces superior clinical outcomes.

Both agents share the GLP-1-class gastrointestinal adverse event profile: nausea, vomiting, and diarrhea are most prominent during dose titration and typically attenuate with continued treatment. The incidence and severity of these effects are comparable across both compounds' Phase 3 programs.

CagriSema-specific considerations:

• Amylin-related nausea: Cagrilintide's activation of area postrema amylin receptors may produce incremental nausea beyond the GLP-1-class baseline, though the REDEFINE 1 discontinuation rate for GI adverse events did not significantly exceed semaglutide monotherapy
• Injection burden: CagriSema currently requires two separate subcutaneous injections per week (semaglutide and cagrilintide administered separately). A co-formulated single-injection product is in development but not yet available

Tirzepatide-specific considerations:

• Post-marketing experience: Tirzepatide has accumulated 2+ years of real-world prescribing data since FDA approval in November 2023, providing pharmacovigilance data that CagriSema lacks
• Single injection: Administered as one subcutaneous injection per week, which may improve patient adherence compared to a two-injection regimen
• GIP-related tolerability: Some evidence suggests GIP receptor co-agonism may modulate GLP-1-induced nausea, potentially contributing to the comparable tolerability seen despite higher weight loss efficacy

The SURMOUNT-5 head-to-head trial comparing tirzepatide to semaglutide reported similar rates of gastrointestinal adverse events between the two agents despite tirzepatide's 47% greater weight loss effect, suggesting the GIP component does not proportionally increase GI side effects.

Tirzepatide holds the regulatory advantage: FDA approval for both obesity (Zepbound, November 2023) and type 2 diabetes (Mounjaro, May 2022), supported by the comprehensive SURMOUNT and SURPASS clinical programs and growing real-world prescribing data. The SURMOUNT-5 head-to-head trial demonstrated tirzepatide achieved -20.2% body weight reduction versus -13.7% for semaglutide at 72 weeks, establishing clear superiority over the leading GLP-1 monotherapy.

CagriSema represents a genuinely different multi-pathway strategy rather than an iterative improvement on GLP-1 agonism. By combining GLP-1R activation with amylin receptor engagement, CagriSema addresses both homeostatic and hedonic appetite through different receptor families. The REDEFINE 1 data (20.4% weight loss at 68 weeks) demonstrates this combination produces clinically meaningful additive efficacy over semaglutide monotherapy.

No head-to-head trial between tirzepatide and CagriSema exists. Indirect cross-trial comparison—tirzepatide 15 mg achieving approximately 22.5% (SURMOUNT-1 extended) versus CagriSema at 20.4% (REDEFINE 1)—is suggestive but limited by differences in trial populations, design, and duration. CagriSema may serve a distinct clinical niche for patients with partial GLP-1 response by adding the amylin pathway, rather than competing directly with tirzepatide for the same population.

FDA Drug Labels: Mounjaro (tirzepatide), Zepbound (tirzepatide). CagriSema does not yet have an FDA-approved label.